2023-10 – Q3 2023 Reporting
Screening of patients in New Zealand improved after visiting the clinical centres involved in SER150 CL-009 study. The broaden of inclusion criteria for recruitment of patients to theSER150 CL-009 study…
2023-02 – Q4 2022 Reporting
New Zealand authorities approved the protocol with dosing of SER150 or placebo for six months. All clinical centers in Australia and New Zealand ready to initiate screening of patients in…
2023-01 – New CEO in Serodus ASA
Serodus ASA’s Board of Directors has in agreement with our CEO Eva Steiness decided to relieve her for the administrative burden to manage Serodus ASA from her permanent address in…
2022-07 – Serodus ASA – Minutes of Annual General Meeting 2022
Download: Presentation AGM 2022 Download: Minutes from General Meeting
2022-05 – 2021 Annual Report
SERODUS ASA - Publishes 2021 Annual Report Download it here